Characterization of metabolites of Δ8,9-dehydroestrone in dogs
✍ Scribed by A. Chandrasekaran; M. Osman; P. Raveendranath; K. Chan; J. A. Scatina; S. F. Sisenwine
- Publisher
- John Wiley and Sons
- Year
- 1995
- Tongue
- English
- Weight
- 527 KB
- Volume
- 30
- Category
- Article
- ISSN
- 1076-5174
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Δ^8,9^‐Dehydroestrone is the fifth most abundant component in the conjugated equine estrogen preparation Premarin®, representing about 2 to 6% of the total steroids in the tablet. The metabolism of this estrogen has been determined in female beagle dogs after acute peroral administration. 17β‐Dihydro‐Δ^8,9^‐dehydroestrone(17β‐Δ^8,9^‐dehydroestradiol) and 17α‐dihydro‐Δ^8,9^dehydroestrone(17α‐Δ^8,9^‐dehydroestradiol) have been identified as the major metabolites in plasma and urine. These metabolites, along with the unchanged drug, were isolated and purified by ether extraction and thin‐layer chromatography of the urine samples after enzyme hydrolysis. The trimethylsilyl ether derivatives of the isolated metabolites were characterized by comparison of their mass spectra and chromatographic properties with those of synthetic reference standards.
📜 SIMILAR VOLUMES
Nalorphine-3-glucuronide dihydrate and nalorphine-6-glucuronide were isolated as urinary metabolites of nalorphine in dogs, and nalorphine-3-ethereal sulfate and nalorphine-3-glucuronide dihydrate were isolated in cats. These metabolites were characterized by UV and IR spectra, phenolic test, nalorp
A three-way crossover study was performed to determine the influence of A'-tetrahydrocannabinol (THC) and ethanol (EtOH) separately upon phencyclidine (PCP) disposition in dogs. Seven dogs were given three single dose treatments: 1.5 mg PCP kg-' i.v., 1.5mg PCP kg-' i.v. with 0.4mgkg-' THC i.v., and
The pharmacokinetics and renal excretion of a trichothecene mycotoxin, verrucarol, were studied in six mongrel dogs following IV administration (0.4 mg kg-I). The fraction of verrucarol excreted intact in the urine ranged from 0.9% to 2.7% of the administered dose. The fraction of verrucarol metabo